Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome

Robert K. Semple () and Bart Vanhaesebroeck ()

Nature, 2018, vol. 558, issue 7711, 523-525

Abstract: Abnormal activity of the enzyme PI3K can drive cancer growth, and mutations in a PI3K subunit can sometimes lead to non-cancerous overgrowth. A cancer drug that inhibits PI3K dramatically reduces such overgrowth.

Keywords: Cancer; Medical research (search for similar items in EconPapers)
Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-018-05365-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:558:y:2018:i:7711:d:10.1038_d41586-018-05365-w

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-018-05365-w

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().